IL2RA and primary cutaneous T-cell non-Hodgkin lymphoma: With overall response rates between 30 and 50%, denileukin diftitox (anti-CD25; Ontak®) was approved in 1999 for the treatment of persistent or relapsed CD25-positive CTCL [154, 155].